Zydus Cadila starts phase 3 trial of Desidustat

17 Apr 2019 Evaluate

Zydus Cadila has started the Phase III trials of Desidustat, an Investigational New Drug targeted at treating anemia in non-dialysis dependent chronic kidney disease (NDD-CKD) patients. This Phase III study will be a multicenter (50- 60 sites), randomized, active-controlled clinical trial to evaluate the efficacy and safety of Desidustat versus Darbepoetin for the treatment of anaemia in patients with chronic kidney disease (CKD) who are not on dialysis. 

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies.

Zydus Lifesciences Share Price

867.30 -11.50 (-1.31%)
02-Feb-2026 10:57 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1608.00
Dr. Reddys Lab 1170.05
Cipla 1296.90
Zydus Lifesciences 867.30
Lupin 2085.70
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×